Antiglioma activity of 2,2′:6′,2″-terpyridineplatinum(II) complexes in a rat model - Effects on cellular redox metabolism

Free Radical Biology and Medicine

Volumn 40, Issue 5, 2006, Pages 763-778

  Ahmadi, Rezvan ^a   Urig, Sabine ^b   Hartmann, Marius ^a   Helmke, Burkhard M ^a   Koncarevic, Sasa ^b   Allenberger, Bianca ^a   Kienhoefer, Christine ^a   Neher, Markus ^a   Steiner, Hans Herbert ^a   Unterberg, Andreas ^a   Herold Mende, Christel ^a   Becker, Katja ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Apoptosis; Free radical; Glioblastoma therapy; Redox regulation; Terpyridineplatinum(II) complexes; Thioredoxin reductase

Indexed keywords

2 MERCAPTOPYRIDINE (4' CHLORO 2,2':6',2″ TERPYRIDINE)PLATINUM NITRATE; 4 MERCAPTOPYRIDINE (4' CHLORO 2,2':6',2″ TERPYRIDINE)PLATINUM NITRATE; CISPLATIN; GLUTATHIONE; PLATINUM COMPLEX; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG BIOAVAILABILITY; GLIOBLASTOMA; IN VIVO STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL PROLIFERATION; GLIOMA; MAGNETIC RESONANCE IMAGING; MALE; ORGANOPLATINUM COMPOUNDS; OXIDATION-REDUCTION; OXIDOREDUCTASES; RATS; RATS, WISTAR; SELENOPROTEINS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MAMMALIA;

EID: 33644655166     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2005.09.031     Document Type: Article

References (59)

1. L.D. Arscott, S. Gromer, R.H. Schirmer, K. Becker, and C.H. Williams Jr. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli Proc. Natl. Acad. Sci. USA 94 1997 3621 3626
2. L. Zhong, E.S. Arnér, J. Ljung, F. Aslund, and A. Holmgren Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue J. Biol. Chem. 273 1998 8581 8591
3. T. Sandalova, L. Zhong, Y. Lindqvist, A. Holmgren, and G. Schneider Proc. Natl. Acad. Sci. USA 98 2001 9533 9538
4. E.S. Arner, and A. Holmgren Physiological functions of thioredoxin and thioredoxin reductase Eur. J. Biochem. 267 2000 6102 6109
5. D. Mustacich, and G. Powis Thioredoxin reductase Biochem. J. 346 2000 1 8
6. K. Becker, S. Gromer, R.H. Schirmer, and S. Mueller Thioredoxin reductase as a pathophysiological factor and drug target Eur. J. Biochem. 267 2000 6118 6125
7. V.N. Gladyshev, V.M. Factor, F. Housseau, and D.L. Hatfield Contrasting pattern of regulation of the antioxidant selenoproteins, thioredoxin reductase, and glutathione peroxidase, in cancer cells Biochem. Biophys. Res. Commun. 251 1998 488 493
8. D.T. Lincoln, W.M.A. Emadi, K.F. Tonisson, and F.M. Clarke The thioredoxin- thioredoxin reductase system: over-expression in human cancer Anticancer Res. 23 2003 2425 2434
9. K. Kahlos, Y. Soini, M. Saily, P. Koistinen, S. Kakko, P. Paakko, A. Holmgren, and V.L. Kinnula Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma Int. J. Cancer 95 2001 198 204
10. T. Sasada, H. Nakamura, S. Ueda, N. Sato, Y. Kitaoka, Y. Gon, A. Takabayashi, G. Spyrou, A. Holmgren, and J. Yodoi Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II) Free Radic. Biol. Med. 27 1999 504 514
11. A.D. Smith, C.A. Guidry, V.C. Morris, and O.A. Levander Aurothioglucose inhibits murine thioredoxin reductase activity in vivo J. Nutr. 129 1999 194 198
12. K.U. Schallreuter, F.K. Gleason, and J.M. Wood The mechanism of action of the nitrosourea antitumour drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase Biochim. Biophys. Acta 1054 1990 14 20
13. S. Gromer, R.H. Schirmer, and K. Becker The 58 kDa mouse selenoprotein is a BCNU-sensitive thioredoxin reductase FEBS Lett. 412 1997 318 320
14. S. Gromer, S. Urig, and K. Becker The thioredoxin system-From science to clinic Med. Res. Rev. 24 2004 40 89
15. S.A. Ross, C.A. Carr, J.-W. Briet, and G. Lowe Transfer of 4′-chloro-2,2′:6′,2″-terpyridine platinum(II) between human serum albumin, glutathione and other thiolate ligands. A possible selective natural transport mechanism for the delivery of platinum(II) drugs to tumour cells Anti-Cancer Drug Des. 15 2000 431 439
16. G. Lowe, A.S. Droz, T. Vilaivan, G.W. Weaver, J.J. Park, J. Pratt, L. Tweedale, and L.R. Kelland Cytotoxicity of 2,2′:6′,2″- terpyridineplatinum(II) complexes against human ovarian carcinoma J. Med. Chem. 42 1999 3167 3174
17. M. Cusumano, M.L. Di Pietro, A. Giennetto, and F. Romano Influence of DNA on the rate of ligand substitution in platinum(II) terpyridine complexes Inorg. Chem. 39 2000 50 55
18. H. Kurosaki, N. Yamakawa, M. Sumimoto, K. Kimura, and M. Goto Interaction of binuclear xylylthiolato(2,2′,2″-terpyridine)platinum(II) complexes with DNA Bioorg. Med. Chem. Lett. 13 2003 825 828
19. K. Becker, C. Herold-Mende, J.J. Park, G. Lowe, and R.H. Schirmer Human thioredoxin reductase is efficiently inhibited by (2,2′:6′,2″- terpyridine)platinum(II) complexes. Possible implications for a noval antitumour strategy J. Med. Chem. 44 2001 2784 2792
20. H.H. Steiner, C. Herold-Mende, M. Bonsanto, K. Geletneky, S. Kunze, and Zur Prognose von Hirntumoren: Epidemiologie, Überlebenszeit und klinischer Verlauf Versicherungsmedizin 50 1998 173 179
21. P. Kleihues, D.N. Louis, B.W. Scheithauer, L.B. Rorke, G. Reifenberger, P.C. Burger, and W.K. Cavenee The WHO classification of tumours of the nervous system J. Neuropathol. Exp. Neurol. 61 2002 215 225
22. C.P. Belani Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumours and myeloma Semin. Oncol. 31 2004 25 33
23. L.M. De Angelis, P.C. Burger, S.B. Green, and H.G. Cairncross Malignant gliomas: who benefits from adjuvant chemotherapy? Ann. Neurol. 44 1998 691 695
24. M.C. Chamberlain, and P.A. Kormanik Practical guidelines for the treatment of malignant gliomas West. J. Med. 168 1998 114 120
25. P.M. Färber, L.D. Arscott, C.H. Williams, K. Becker, and R.H. Schirmer Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue FEBS Lett. 422 1998 311 314
26. M. Hartmann, R. Junkers, C. Herold-Mende, R. Ahmadi, and S. Heiland Pseudonormalization of diffusion weighted images: magnetic resonance imaging in an animal model (C6-glioma) Rofo 177 2005 114 118
27. M.M. Mueller, C. Herold-Mende, D. Riede, H.H. Steiner, M. Lange, and N.E. Fusenig Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumour progression Am. J. Pathol. 155 1999 1557 1567
28. K. Becker, B. Krebs, and R.H. Schirmer Protein-chemical standardisation of the erythrocyte glutathione reductase activation test (EGRAC TEST). Application to hypothyroidism Int. J. Vit. Nutr. Res. 61 1991 180 187
29. E. Beutler Redox cell metabolism-a manual of biochemical methods 1984 Grune and Stratton London
30. K. Becker, M. Gui, A. Traxler, and R.H. Schirmer Redox processes in malaria and other parasitic diseases. Determination of intracellular glutathione Histochemistry 102 1994 389 395
31. N.J. Miller, C. Rice-Evans, M.J. Davies, V. Gopinathan, and A. Milner A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates Clin. Sci. 84 1993 407 412
32. C. Rice-Evans, and N.J. Miller Total antioxidant status in plasma and body fluids Methods Enzymol. 234 1994 279 293
33. S. Gromer, L.D. Arscott, C.H. Williams Jr., R.H. Schirmer, and K. Becker Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds J. Biol. Chem. 273 1998 20096 20101
34. C. Herold-Mende, H.H. Steiner, T. Andl, D. Riede, A. Buttler, C. Reisser, N.E. Fusenig, and M.M. Mueller Expression and functional significance of vascular endothelial growth factor receptors in human tumour cells Lab. Invest. 79 1999 1573 1582
35. B. Grobben, P.P. De Deyn, and H. Slegers Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion Cell Tissue Res. 310 2002 257 270
36. I. Harting, M. Hartmann, G. Jost, C. Sommer, R. Ahmadi, S. Heiland, and K. Sartor Differentiating primary central nervous system lymphoma from glioma in humans using localized proton magnetic resonance spectroscopy Neurosci. Lett. 342 2003 163 166
37. M.E. Anderson Glutathione: an overview of biosynthesis and modulation Chem. Biol. Interact. 111-112 1998 1 14
38. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs Cancer Res. 46 1986 6387 6392
39. E.S.J. Arnér, H. Nakamura, T. Sasada, J. Yodoi, A. Holmgren, and G. Spyrou Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum(II) and its major metabolite, the glutathione-platinum complex Free Radic. Biol. Med. 31 2001 1170 1178
40. I. Pommepuy, F. Terro, B. Petit, F. Trimoreau, V. Bellet, S. Robert, J. Hugon, F. Labrousse, and C. Yardin Brefeldin A induces apoptosis and cell cycle blockade in glioblastoma cell lines Oncology 64 2003 459 467
41. R.P. Huang, M.Z. Hossain, R. Huang, J. Gano, Y. Fan, and A.L. Boynton Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells Int. J. Cancer. 92 2001 130 138
42. M. Begemann, S.A. Kashimawo, D.F. Heitjan, P.B. Schiff, J.N. Bruce, and I.B. Weinstein Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity Anticancer Res. 18 1998 2275 2282
43. S. Bursztajn, J.-J. Feng, N. Anil, and S.A. Berman Differential responses of human neuroblastoma and glioblastoma to apoptosis Mol. Brain Res. 91 2001 57 72
44. B.-L. Mau, and G. Powis Mechanism-based inhibition of thioredoxin reductase by antitumour quinoid compounds Biochem. Pharmacol. 43 1992 1613 1620
45. Urig, S.; Ahmadi, R.; Herold-Mende, C.; Alber, D.; Becker, K. Platinum(II) complexes: inhibition of thioredoxin reductase in glioblastoma therapy. Flavins and Flavoproteins, volume 15. In press; 2005.
46. G.K. Balendiran, R. Dabur, and D. Fraser The role of glutathione in cancer Cell Biochem. Funct. 22 2004 343 352
47. J.D. Hayes, J.U. Flanagan, and I.R. Jowsey Glutathione transferases Annu. Rev. Pharmacol. Toxicol. 45 2005 51 88
48. L.C. Clark, G.F. Combs Jr., B.W. Turnbull, E.H. Slate, D.K. Chalker, J. Chow, L.S. Davis, R.A. Glover, G.F. Graham, E.G. Gross, A. Krongrad, J.L. Lesher Jr., H.K. Park, B.B. Sanders Jr., C.L. Smith, and J.R. Taylor Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group JAMA 276 1996 1957 1963
49. EA.A.L. l-Yazigi, I. Saleh, and O. Al-Mefty Concentrations of Ag, Al, Au, Bi, Cd, Cu, Pb, Sb, and Se in cerebrospinal fluid of patients with cerebral neoplasms Clin. Chem. 30 1984 1358 1360
50. H. Savolainen Superoxide dismutase and glutathione peroxidase activities in rat brain Res. Commun. Chem. Pathol. Pharmacol. 21 1978 173 176
51. J.D. Holding, W.E. Lindup, C. Van Lear, G.C.M. Vreeburg, V. Schiling, J.A. Wilson, and P.M. Stell Phase-I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck Br. J. Clin. Pharmacol. 33 1992 75 81
52. A. Yokomizo, M. Ono, H. Nanri, Y. Makino, T. Ohga, M. Wada, T. Okamoto, J. Yodoi, M. Kuwano, and K. Kohno Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide Cancer Res. 55 1995 4293 4296
53. S. Ueda, H. Masutani, H. Nakamura, T. Tanaka, M. Ueno, and J. Yodoi Redox control of cell death Antioxid. Redox Signal. 4 2002 405 414
54. Y. Soini, K. Kahlos, U. Napankangas, R. Kaarteenaho-Wiik, M. Sally, P. Koistine, P. Paaakko, A. Holmgren, and V.L. Kinnula Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma Clin. Cancer Res. 7 2001 1750 1757
55. M. Pallis, T.D. Bradshaw, A.D. Westwell, M. Grundy, M.F.G. Stevens, and N. Russell Induction of apoptosis without redox catastrophe by thioredoxin-inhibitory compounds Biochem. Pharmacol. 66 2003 1695 1705
56. K. Anestal, and E.S. Arnér Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine J. Biol. Chem. 278 2003 15966 15972
57. I. Jeremias, H.H. Steiner, A. Benner, K.-M. Debatin, and C. Herold-Mende Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells Acta Neurochir. 146 2004 721 729
58. I.F. Parney, and S.M. Chang Current chemotherapy for glioblastoma Cancer J. 9 2003 149 156
59. V. Jendrossek, C. Belka, and M. Bamberg Novel chemotherapeutic agents for the treatment of glioblastoma multiforme Expert Opin. Invest. Drugs 12 2003 1899 1924